Hansa Biopharma year-end report 2021
· Commercial launch and market access efforts in Europe progressing as planned; new multiregional commercialization partnership with Medison Pharma · First patients enrolled into the pivotal U.S. ConfIdeS study · Agreement established with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease · Platform strategy: Hansa to explore desensitization treatment in allogeneic hematopoietic stem cell transplantation · Year-end cash position of SEK 889 million; Hansa financed into 2023, as previously guidedLund, Sweden February 3, 2022